Skip Ribbon Commands
Skip to main content
Navigate Up
EnglishFrancais
Current Year Centre for Addiction
and Mental Health

A FAAH Better Thing for Cannabis Users: New Insights May Aid Development of Treatments for Cannabis Use Disorder

Research from CAMH’s Campbell Family Mental Health Research Institute was profiled in this news release from Biological Psychiatry

Philadelphia, PA, October 25, 2016 – A new paper in Biological Psychiatry reports that chronic cannabis users have reduced levels of an enzyme called fatty acid amide hydrolase (FAAH). The enzyme has been considered for treatment for cannabis dependence because it breaks down substances made in the brain that have cannabis-like effects, called endocannabinoids, rendering them inactive.

“This exciting study sheds new light on cannabis dependence,” said John Krystal, Editor of Biological Psychiatry. The study provides clues that may help develop treatments for cannabis use disorder for which none currently exist, due in part to our poor understanding of how cannabis affects brain systems.

In the study, first author Isabelle Boileau and colleagues from the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada used a new positron emission tomography radiotracer, [11C]CURB, to measure FAAH levels in 10 active cannabis users, who had been using cannabis for an average of 18 years but were on recent withdrawal for the study, and 22 control subjects. They also analyzed blood, urine, and hair samples for traces of cannabinoids.

Dr. Isabelle Boileau
Dr. Isabelle Boileau

FAAH levels were reduced by 14–20 per cent in chronic cannabis users compared with people who did not use cannabis. The low FAAH levels were associated with higher levels of cannabinoids in blood and urine, suggesting FAAH levels correlate with chronic and recent cannabis use.

Cannabis produces its key effects by stimulating CB1 cannabinoid receptors, the target of endocannabinoids. Together the data of the new study suggest that among chronic users, the enhanced stimulation of CB1 receptors by cannabis ingestion, which is known to downregulate CB1 receptors could, during acute cessation, lead to a suppression of FAAH activity in an attempt to restore “normal” CB1 stimulation by endogenous cannabinoids.

According to Krystal, the findings raise the possibility that normalizing cannabinoid CB1 receptor activity might play a role in reducing cannabis use and problems with impulse control in users. The finding that heavy almost-daily cannabis use downregulates levels of FAAH after overnight cessation from cannabis use may explain the relative absence of withdrawal symptoms in very early abstinence, says Boileau, “and suggests that strategies aimed at keeping levels of this enzyme down might help reduce cannabis withdrawal symptoms.”

 

CAMH Switchboard 416-535-8501
CAMH General Information Toronto: 416-595-6111 Toll Free: 1-800-463-6273
Connex Ontario Help Lines
Queen St.
1001 Queen St. W
Toronto, ON
M6J 1H4
Russell St.
33 Russell St.
Toronto, ON
M5S 2S1
College St.
250 College St.
Toronto, ON
M5T 1R8
Ten offices across Ontario